Phaseline

Targets › FCER1A

FCER1A (High affinity immunoglobulin epsilon receptor subunit alpha): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 3; Immunology; next expected readout Jun 2027.

High-affinity receptor for immunoglobulin epsilon/IgE. Mediates IgE effector functions in myeloid cells. Upon IgE binding and antigen/allergen cross-linking initiates signaling pathways that lead to myeloid cell activation and differentiation. (UniProt, P12319)

Open in Phaseline: the race on FCER1A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The University of Texas Medical Branch, GalvestonCromolyn sodium (topical 4%)
Mast cell stabilizer
FCER1APhase 3Burn ScarDec 2027
YuhanLesigercept
High-affinity IgE receptor (FcεRI) antagonist
FCER1APhase 2Allergic DiseasesJun 2027

Conditions

Allergic Diseases (1) Burn Scar (1)

Modalities

antibody (1), small molecule (1)

Companies

Yuhan (1) The University of Texas Medical Branch, Galveston (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.